Bristol Myers Squibb’s portfolio includes cell therapies for cancer made from a patient’s own immune cells. The pharmaceutical giant also wants a place in the next generation of cell therapies that ...
The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...
New approach to adjuvant therapy in high-risk melanoma patients. Background: With the enhanced understanding of the immune response to a tumor, new immunotherapeutic agents may expand treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results